Budget Impact Analysis for Payers: Building a Model That Survives Scrutiny

A price can be justified on value and still fail on affordability. Budget impact analysis answers a different question from cost-effectiveness: what will this medicine cost the payer, year by year, if it is reimbursed?

Why budget impact decides outcomes

Cost-effectiveness describes value for money per patient. Budget impact describes the total bill. A therapy with a favourable ratio can still be delayed or restricted if the projected spend is large relative to the payer’s pharmaceutical budget. In Greece, the published description of the assessment process lists budget impact alongside clinical benefit, comparison with existing reimbursed treatments, reliability of clinical data and cost-effectiveness, and the negotiation committee advises on it during price discussions.

What a credible model contains

Payers read budget impact models for transparency before they read them for results. The strongest submissions make every assumption visible and traceable to a source.

  • Eligible population: epidemiology, diagnosis rates and the share of patients who are actually treatable, built from local data where it exists.
  • Uptake curve: a realistic share of patients treated each year, justified by clinical practice, capacity and competing options rather than by aspiration.
  • Comparator mix: the current market without your product versus the market with it, including the products it will replace.
  • Costs beyond the drug: administration, monitoring, adverse events and any offsets elsewhere in the care pathway, stated separately.
  • Time horizon: usually a short horizon of a few years, with yearly results shown, because payers budget annually.

Where models lose credibility

Three weaknesses recur. Uptake is assumed to be fast and unconstrained, which looks optimistic. Displacement of existing therapies is overstated, which makes net cost look lower than payers expect. And scenarios are missing, so the reader cannot see how the result moves if the population or price changes. A model that shows its own range of outcomes is easier to trust than one presenting a single confident figure.

Linking budget impact to the commercial offer

The model should align with the pricing and agreement strategy. If a discount, rebate or managed entry agreement is part of the proposal, the net budget effect after those mechanisms should be calculated and shown, since the payer will do the same calculation. Reimbursement is also shaped by national rebate and clawback arrangements, so assumptions should be checked against the rules in force at submission.

Questions to ask before you submit

Before a model leaves the building, test it the way a payer would. Can an independent reader rebuild the eligible population from the cited sources? Does the uptake assumption match what has happened with comparable launches in the same therapy area? If the product is priced the same in every scenario, have the likely discounts and agreements been reflected? And if the payer halves the uptake or doubles the eligible population, does the narrative still hold?

It also helps to separate the facts from the judgement. Epidemiology and list prices are facts; uptake and displacement are judgements. Labelling them as such, and explaining the reasoning behind each judgement, gives a reviewer a reason to engage with the model rather than discard it. Finally, keep a short plain-language summary alongside the spreadsheet, because committee members are rarely modellers.

How PQRA helps

PQRA supports market access planning for Greece and wider European markets, including structuring the evidence a payer will test and aligning the economic narrative with the regulatory and pricing strategy. We can help review assumptions and prepare submissions for the relevant authorities.

If you are preparing a reimbursement submission and want a second look at the economic case, Contact PQRA.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *